HENDERSON, Nev. – Leading Edge, a biotechnology company developing novel cannabinoid therapies and innovative delivery systems, announced Monday that former professional basketball player and cannabis advocate John Salley has been appointed as executive vice president of marketing, effective immediately. Salley will help Leading Edge market Cannavera, its lineup of CBD-based topical pain and inflammation solutions.
HENDERSON, Nev. — Leading Edge Pharms, a biotechnology company developing novel cannabinoid therapies and innovative delivery platforms, Wednesday announced its partnership with Independent Pharmacy Alliance (IPA), a trade group and retail pharmacy buying cooperative, to make LEP’s Hemp/CBD-based Cannavera Topical Pain Relief products available to IPA’s 3,100 member pharmacies, located in New York, New Jersey,
HENDERSON, Nev. — Leading Edge Pharms, (LEP) a biotechnology company developing novel cannabinoid therapies and innovative delivery systems, announced the results of a Tioga Research-led study, indicating that its proprietary cannabidiol-based (CBD) pain relief and anti-inflammatory agent, Silvidiol, effectively permeates the epidermis to reach somatic and neuropathic sensory receptors below the surface of the skin.
HENDERSON, Nev. — CARE Pharmacies Cooperative Inc. (CARE), a growing independent retail drug chain serving local communities throughout the United States, and Leading Edge Pharms, Inc. (Leading Edge), a biotechnology company developing novel cannabinoid therapies and innovative delivery platforms, announced today a preferred provider relationship for Leading Edge to provide Cannavera Topical Pain Relief products to CARE
